| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Nuvectis Pharma, Inc. (NVCT) has 7 insiders with recent SEC Form 4 filings, including 4 buys and 0 sells. NVCT is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 3.68M | $71.94M | - | |
| 10% | 3.14M | $61.38M | - | |
| Other | 1.81M | $35.35M | - | |
| Other | 1.79M | $35.09M | - | |
| VP | 200.1K | $3.92M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 7, 2022 | Poradosu Enrique70 | Chief Science &Business Off | Buy | 4,600 | $3.44 | $15,834.00 | +0.2% | +89.4% | +37.0% | |
| Feb 7, 2022 | Shemesh Shay72 | Chief Development Officer | Buy | 2,946 | $3.41 | $10,033.62 | +0.1% | +89.4% | +37.0% |